PMID- 20823838
OWN - NLM
STAT- MEDLINE
DCOM- 20110119
LR  - 20220318
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
VI  - 105
IP  - 12
DP  - 2010 Dec
TI  - Prevalence and symptom pattern of pathologic esophageal acid reflux in patients 
      with functional dyspepsia based on the Rome III criteria.
PG  - 2626-31
LID - 10.1038/ajg.2010.351 [doi]
AB  - OBJECTIVES: To determine the prevalence and symptom pattern of pathologic 
      esophageal acid reflux (PEAR) in patients with functional dyspepsia (FD) using 
      the Rome III criteria, and to explore the value of a proton pump inhibitor (PPI) 
      test in distinguishing the patients with and those without PEAR among FD 
      patients. METHODS: Consecutive FD patients who fulfilled the Rome III criteria 
      without predominant typical reflux symptoms (i.e., heartburn or regurgitation) 
      were enrolled. All patients underwent upper endoscopy and an ambulatory 24-h pH 
      monitoring. PEAR was defined as the percentage total time for which a pH value <4 
      was >4.2% in the distal esophagus. Then, patients were treated with rabeprazole 
      10 mg twice daily for 28 days. The symptom scores were measured by the frequency 
      score multiplied by the severity scores of the predominant symptom before and at 
      the end of the treatment, and the "PPI test" was defined as positive if the 
      overall scores of the predominant dyspeptic symptom in the fourth week decreased 
      by >50% compared with those of the baseline. RESULTS: One hundred eighty-six FD 
      patients were enrolled, with predominant symptoms of epigastric pain (n=68), 
      epigastric burning (n=47), bothersome postprandial fullness (n=54), and early 
      satiation (n=17). The prevalence of PEAR was 31.7%, with the highest percentage 
      (48.9%) in patients with epigastric burning as their predominant symptom. The 
      prevalence of PEAR in patients with postprandial distress syndrome (PDS) and 
      epigastric pain syndrome (EPS) were 36.6% (26/71) and 28.7% (33/115), 
      respectively. Overall, 63.4% were positive for the "PPI test"; the rates were 
      51.5, 85.0, 66.7, and 41.1% in patients with epigastric pain, epigastric burning, 
      bothersome postprandial fullness, and early satiation as their predominant 
      symptoms, respectively (chi(2)=17.59, P=0.001). The positive rates were 65.5 and 
      60.6% in patients with PDS and EPS, respectively (chi(2)=0.41, P=0.522). The 
      sensitivity and specificity of the "PPI test" in distinguishing FD patients with 
      PEAR was 83.1 and 45.7%, respectively. CONCLUSIONS: PEAR is present in almost one 
      third of FD patients; the prevalence is  approximately 50% in those with epigastric burning. 
      The "PPI test" has a limited value in distinguishing the FD patients with and 
      those without PEAR.
FAU - Xiao, Ying-Lian
AU  - Xiao YL
AD  - Department of Gastroenterology and Hepatology, First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, China.
FAU - Peng, Sui
AU  - Peng S
FAU - Tao, Jin
AU  - Tao J
FAU - Wang, An-Jiang
AU  - Wang AJ
FAU - Lin, Jin-Kun
AU  - Lin JK
FAU - Hu, Pin-Jin
AU  - Hu PJ
FAU - Chen, Min-Hu
AU  - Chen MH
LA  - eng
PT  - Journal Article
DEP - 20100907
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
SB  - IM
CIN - Am J Gastroenterol. 2010 Dec;105(12):2632-4. PMID: 21131930
CIN - Am J Gastroenterol. 2011 Jun;106(6):1168; author reply 1168-9. PMID: 21637272
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Chi-Square Distribution
MH  - Dyspepsia/classification/*drug therapy/*epidemiology/physiopathology
MH  - Esophageal pH Monitoring
MH  - Esophagoscopy
MH  - Female
MH  - Gastroesophageal Reflux/classification/*drug 
      therapy/*epidemiology/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Rabeprazole
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2010/09/09 06:00
MHDA- 2011/01/20 06:00
CRDT- 2010/09/09 06:00
PHST- 2010/09/09 06:00 [entrez]
PHST- 2010/09/09 06:00 [pubmed]
PHST- 2011/01/20 06:00 [medline]
AID - ajg2010351 [pii]
AID - 10.1038/ajg.2010.351 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2010 Dec;105(12):2626-31. doi: 10.1038/ajg.2010.351. Epub 
      2010 Sep 7.